# Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism

**Authors:** Viola Viola, Marlene Aguilar, Maria Liza Duremdes Nava, Alessandra Celli, Reina Armamento-Villareal, Yoann Barnouin, Nicola Napoli, Nagireeddy Putluri, Clifford Qualls, Dennis T. Villareal

PMC · DOI: 10.3389/fendo.2025.1719749 · Frontiers in Endocrinology · 2026-02-09

## TL;DR

Adding testosterone to lifestyle therapy improves muscle metabolism in older men with obesity and low testosterone, helping preserve muscle and aerobic function.

## Contribution

The study identifies glycolysis as the key metabolic pathway enhanced by testosterone during lifestyle therapy in older men.

## Key findings

- Testosterone plus lifestyle therapy increased glycolytic intermediates and lactate in skeletal muscle.
- Glycolysis was the only metabolic pathway significantly enhanced by testosterone treatment.
- Glycolytic activation correlated with improved aerobic capacity and reduced metabolic syndrome markers.

## Abstract

Weight loss in older men with obesity and hypogonadism accelerates musculoskeletal decline, yet the underlying metabolic mechanisms remain unclear. Testosterone replacement therapy (TRT), when added to lifestyle therapy (LT), mitigates this decline, but its metabolic basis has not been defined. We examined skeletal muscle metabolomic adaptations to LT with or without TRT, focusing on glycolysis, the pentose phosphate pathway (PPP), the tricarboxylic acid (TCA) cycle, and carnitine metabolism to identify dominant pathways of metabolic adaptation.

Randomized, double-blind, placebo-controlled trial (LITROS).

Eighty-three men aged 65 years or older with obesity (BMI ≥30 kg/m2), hypogonadism (testosterone <10.4 nmol/L), and frailty (Physical Performance Test score ≤31) were randomized to 26 weeks of LT plus TRT (LT+TRT) or LT plus placebo (LT+Pbo). A metabolomic substudy was performed in 44 participants, who underwent serial biopsies of the vastus lateralis for targeted LC-MS/MS analysis of intermediates in glycolysis, PPP, TCA cycle, and carnitine metabolism.

Among the pathways examined, only glycolysis showed a consistent and significant response to LT+TRT versus LT+Pbo (between-group p = 0.005). This response was characterized by increases in preparatory (G6P/F6P, FBP) and payoff (3PG, 2PG, PEP) intermediates, along with higher lactate concentrations, whereas pyruvate remained stable. The PPP showed limited changes, and neither the TCA cycle nor carnitine metabolites exhibited consistent patterns. In LT+TRT, the glycolysis factor score was positively correlated with VO2peak (r=0.47, p = 0.04) and inversely correlated with triglycerides (r=–0.52, P = 0.01) and the metabolic syndrome score (r=–0.48, p = 0.02). No significant correlations were observed in LT+Pbo.

TRT during LT selectively enhances skeletal muscle glycolysis, identifying glycolic activation as the dominant metabolic adaptation in this mechanistic study. By increasing glycolytic flux under calorie restriction, TRT may produce efficient ATP generation while conserving amino acids, supporting muscle and bone preservation and improving aerobic and cardiometabolic function in older men with obesity and hypogonadism.

## Linked entities

- **Diseases:** obesity (MONDO:0011122), hypogonadism (MONDO:0002146), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** NPEPPS (aminopeptidase puromycin sensitive) [NCBI Gene 9520] {aka AAP-S, MP100, PSA}, SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** venous thromboembolism (MESH:D054556), testosterone deficiency (MESH:D007153), loss of muscle and bone mass (MESH:D001847), Weight loss (MESH:D015431), osteoporosis (MESH:D010024), impaired musculoskeletal health (MESH:D009140), lean mass loss (MESH:D013851), sleep apnea (MESH:D012891), sarcopenia (MESH:D055948), prostate cancer (MESH:D011471), Metabolic syndrome (MESH:D024821), cardiopulmonary disease (MESH:D006323), metabolic and functional decline (MESH:D060825), metabolic resistance (MESH:D060467), fatigued (MESH:D005221), Obesity (MESH:D009765), muscle mass (MESH:C536030), Frailty (MESH:D000073496), hypogonadism (MESH:D007006), caloric deficit (MESH:D009461), metabolic dysfunction (MESH:D008659)
- **Chemicals:** isobutyryl-carnitine (MESH:C020381), fructose-6-phosphate (MESH:C027618), fructose-1,6-bisphosphate (MESH:C029063), Carnitine (MESH:D002331), F6P (-), Lidocaine (MESH:D008012), octanoyl-carnitine (MESH:C008698), acylcarnitines (MESH:C116917), serine (MESH:D012694), fatty acid (MESH:D005227), amino acid (MESH:D000596), chloroform (MESH:D002725), 6-Phosphogluconate (MESH:C008884), ATP (MESH:D000255), citrate (MESH:D019343), glucose (MESH:D005947), fumarate (MESH:D005650), acid (MESH:D000143), oxygen (MESH:D010100), pyruvate (MESH:D019289), methanol (MESH:D000432), Triglyceride (MESH:D014280), TCA (MESH:D014233), glyceraldehyde-3-phosphate (MESH:D005986), Pentose phosphate (MESH:D010428), lactate (MESH:D019344), glucose-6-phosphate (MESH:D019298), butyryl-carnitine (MESH:C427065), nitrogen (MESH:D009584), glucose-1,6-bisphosphate (MESH:C016473), 3-phosphoglycerate (MESH:C005156), acetyl-CoA (MESH:D000105), Androgel (MESH:D013739), water (MESH:D014867), PEP (MESH:D010728), glycerol-3-phosphate (MESH:C029620), 2-phosphoglycerate (MESH:C008885), malate (MESH:C030298), ketone body (MESH:D007657), pentose (MESH:D010429), propionyl-carnitine (MESH:C003223)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914099/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914099/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914099/full.md

---
Source: https://tomesphere.com/paper/PMC12914099